CytomX Therapeutics (CTMX) Financials

$3.78 -0.01 (-0.26%)

Closing price 04:00 PM Eastern

Extended Trading

$3.76 -0.02 (-0.42%)

As of 05:10 PM Eastern

Annual Income Statements for CytomX Therapeutics

This table shows CytomX Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-42	-59	-43	-85	-133	-65	-116	-99	-0.57	32	-20
Consolidated Net Income / (Loss)	-35	-59	-43	-85	-133	-65	-116	-99	-0.57	32	-17
Net Income / (Loss) Continuing Operations	-35	-59	-43	-85	-133	-65	-116	-99	-0.57	32	-17
Total Pre-Tax Income	-35	-59	-44	-70	-133	-79	-116	-99	3.32	32	-17
Total Operating Income	-33	-60	-46	-78	-141	-81	-116	-101	-6.48	25	-22
Total Gross Profit	7.71	15	72	60	27	68	37	53	101	138	76
Total Revenue	7.71	15	72	60	27	68	37	53	101	138	76
Operating Revenue	7.71	15	72	60	27	68	37	53	101	138	76
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	41	75	118	137	168	149	153	154	108	113	99
Selling, General & Admin Expense	13	20	26	34	37	36	39	43	30	30	30
Research & Development Expense	28	55	92	104	132	113	114	112	78	83	69
Total Other Income / (Expense), net	-2.16	0.67	2.65	7.57	8.23	1.81	0.17	2.02	9.81	7.10	5.23
Interest & Investment Income	1.32	0.74	2.67	7.64	8.37	1.84	0.26	1.68	9.84	7.14	5.21
Other Income / (Expense), net	-1.74	-0.07	-0.03	-0.07	-0.14	-0.03	-0.08	0.34	-0.03	-0.04	0.03
Income Tax Expense	0.01	-0.02	-0.51	14	-0.43	-14	0.00	0.00	3.89	0.22	0.24
Basic Earnings per Share	($4.90)	($1.63)	($1.16)	-	($2.93)	($1.40)	($1.81)	($1.51)	($0.01)	$0.38	($0.15)
Weighted Average Basic Shares Outstanding	8.60M	36.23M	37.17M	41.66M	45.34M	46.15M	64.15M	65.74M	73.81M	84.44M	137.94M
Diluted Earnings per Share	($4.90)	($1.63)	($1.16)	-	($2.93)	($1.40)	($1.81)	($1.51)	($0.01)	$0.38	($0.15)
Weighted Average Diluted Shares Outstanding	8.60M	36.23M	37.17M	41.66M	45.34M	46.15M	64.15M	65.74M	73.81M	84.75M	137.94M
Weighted Average Basic & Diluted Shares Outstanding	8.60M	36.23M	37.17M	41.66M	45.34M	46.15M	65.39M	66.23M	67.72M	80.10M	170.19M

This table shows CytomX Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-1.09	2.99	0.84	14	-6.53	5.74	19	24	-0.15	-14	-30
Consolidated Net Income / (Loss)	-1.09	2.99	0.84	14	-6.53	5.74	19	24	-0.15	-14	-27
Net Income / (Loss) Continuing Operations	-1.09	2.99	0.84	14	-6.53	5.74	19	24	-0.15	-14	-27
Total Pre-Tax Income	-1.09	5.82	1.91	14	-6.48	5.80	19	24	-0.09	-14	-26
Total Operating Income	-3.35	3.12	-0.61	12	-8.45	4.11	18	23	-1.29	-16	-28
Total Gross Profit	25	26	27	41	25	33	38	51	19	5.96	0.66
Total Revenue	25	26	27	41	25	33	38	51	19	5.96	0.66
Operating Revenue	25	26	27	41	25	33	38	51	19	5.96	0.66
Total Operating Expenses	28	23	27	30	34	29	20	28	20	22	29
Selling, General & Admin Expense	7.40	6.81	7.83	7.75	8.40	7.95	5.62	9.43	6.62	6.43	7.36
Research & Development Expense	21	16	19	22	25	21	15	19	13	15	21
Total Other Income / (Expense), net	2.26	2.69	2.51	2.18	1.97	1.69	1.26	0.97	1.20	1.60	1.48
Interest & Investment Income	2.31	2.70	2.50	2.19	1.97	1.69	1.28	0.96	1.18	1.59	1.48
Other Income / (Expense), net	-0.05	-0.01	0.01	-0.01	-0.00	-0.01	-0.02	0.01	0.02	0.01	-0.01
Income Tax Expense	0.00	2.82	1.07	0.05	0.05	0.06	0.06	0.06	0.06	0.06	0.06
Basic Earnings per Share	($0.02)	$0.04	$0.02	$0.17	($0.08)	$0.07	$0.22	$0.27	$0.00	($0.09)	($0.33)
Weighted Average Basic Shares Outstanding	66.54M	80.73M	73.81M	82.03M	84.88M	85.09M	84.44M	87.12M	129.08M	165.00M	137.94M
Diluted Earnings per Share	($0.02)	$0.04	$0.02	$0.17	($0.08)	$0.07	$0.22	$0.27	$0.00	($0.09)	($0.33)
Weighted Average Diluted Shares Outstanding	66.54M	80.99M	73.81M	82.63M	84.88M	85.20M	84.75M	87.15M	129.08M	165.00M	137.94M
Weighted Average Basic & Diluted Shares Outstanding	66.77M	66.99M	67.72M	-	78.12M	78.26M	80.10M	80.62M	164.91M	169.44M	170.19M

This table details how cash moves in and out of CytomX Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-4.57	45	73	70	-59	3.43	14	-12	-176	21	-25
Net Cash From Operating Activities	-29	-2.03	170	-76	-140	5.26	-119	-111	-56	-86	-76
Net Cash From Continuing Operating Activities	-27	-2.03	170	-76	-140	5.26	-119	-111	-56	-86	-76
Net Income / (Loss) Continuing Operations	-35	-59	-43	-85	-133	-65	-116	-99	-0.57	32	-17
Consolidated Net Income / (Loss)	-35	-59	-43	-85	-133	-65	-116	-99	-0.57	32	-17
Depreciation Expense	-1.21	1.73	1.52	1.74	2.46	2.43	2.56	2.30	2.03	1.62	1.23
Amortization Expense	1.11	1.66	0.52	-1.56	-2.08	-0.09	0.42	0.09	-7.27	-5.17	-2.06
Non-Cash Adjustments To Reconcile Net Income	-0.79	14	212	17	23	18	16	17	12	12	11
Changes in Operating Assets and Liabilities, net	8.85	39	-0.46	-7.98	-31	50	-22	-31	-63	-126	-69
Net Cash From Investing Activities	-131	46	-121	5.93	80	-19	22	98	-151	100	-60
Net Cash From Continuing Investing Activities	-131	46	-121	5.93	80	-19	22	98	-151	100	-60
Purchase of Property, Plant & Equipment	-1.59	-2.18	-1.56	-3.79	-3.50	-2.31	-1.61	-1.74	-0.84	-0.31	-0.22
Purchase of Investments	-251	-122	-219	-205	-175	-199	-100	0.00	-425	-155	-193
Sale and/or Maturity of Investments	123	170	99	214	258	183	124	100	275	256	133
Net Cash From Financing Activities	153	1.00	24	140	1.63	17	110	0.65	30	7.52	110
Net Cash From Continuing Financing Activities	153	1.00	24	140	1.63	17	110	0.65	30	7.52	110
Issuance of Common Equity	82	0.93	24	140	1.63	17	110	0.65	30	7.52	110

This table details how cash moves in and out of CytomX Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	1.18	-32	-8.85	19	7.06	-2.56	-2.52	9.55	1.44	-15	-21
Net Cash From Operating Activities	-25	-18	-22	-26	-20	-21	-20	-21	-16	-16	-23
Net Cash From Continuing Operating Activities	-25	-18	-22	-26	-20	-21	-20	-21	-16	-16	-23
Net Income / (Loss) Continuing Operations	-1.09	2.99	0.84	14	-6.53	5.74	19	24	-0.15	-14	-27
Consolidated Net Income / (Loss)	-1.09	2.99	0.84	14	-6.53	5.74	19	24	-0.15	-14	-27
Depreciation Expense	0.57	0.45	0.45	0.43	0.42	0.39	0.38	0.35	0.31	0.10	0.47
Amortization Expense	-1.69	-1.90	-2.19	-1.83	-1.40	-1.18	-0.75	-0.42	-0.36	-0.60	-0.68
Non-Cash Adjustments To Reconcile Net Income	3.29	2.17	3.52	2.89	2.89	3.03	3.05	3.09	2.54	2.52	3.04
Changes in Operating Assets and Liabilities, net	-26	-22	-25	-41	-15	-29	-41	-48	-18	-3.33	0.43
Net Cash From Investing Activities	26	-43	13	45	22	18	15	31	-76	0.44	-14
Net Cash From Continuing Investing Activities	26	-43	13	45	22	18	15	31	-76	0.44	-14
Purchase of Property, Plant & Equipment	-0.52	-0.01	-0.27	-0.12	-0.10	-0.02	-0.08	-0.12	-0.03	0.13	-0.20
Purchase of Investments	-73	-93	-112	0.00	-93	-12	-50	-20	-109	-20	-44
Sale and/or Maturity of Investments	100	50	125	45	115	31	65	51	33	20	30
Net Cash From Financing Activities	0.32	30	0.24	0.17	5.10	-	2.25	0.00	94	0.25	17
Net Cash From Continuing Financing Activities	0.32	30	0.24	0.17	5.10	-	2.25	0.00	94	0.25	17
Issuance of Common Equity	0.32	30	0.24	0.17	5.10	-	2.25	0.00	94	0.25	17

This table presents CytomX Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	197	199	398	457	341	359	339	261	202	121	152
Total Current Assets	190	188	389	445	303	324	310	237	183	107	144
Cash & Equivalents	60	105	178	248	188	192	206	194	17	38	13
Short-Term Investments	127	77	197	189	108	124	100	0.00	157	63	124
Accounts Receivable	0.74	2.31	10	0.10	0.01	0.80	0.79	36	3.43	3.10	2.01
Prepaid Expenses	2.30	3.90	4.35	9.25	7.18	7.10	4.29	7.47	5.00	3.58	4.86
Plant, Property, & Equipment, net	3.48	4.39	4.22	6.93	7.37	6.95	5.96	5.07	3.96	2.47	1.30
Total Noncurrent Assets	3.98	6.59	4.83	4.70	31	28	23	19	15	11	6.34
Goodwill	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
Intangible Assets	1.75	1.75	1.60	1.46	1.31	1.17	1.02	0.88	0.73	0.58	0.44
Other Noncurrent Operating Assets	0.36	3.89	2.27	2.29	28	26	21	17	13	9.23	4.95
Total Liabilities & Shareholders' Equity	197	199	398	457	341	359	339	261	202	121	152
Total Liabilities	71	121	328	326	290	366	340	347	249	121	53
Total Current Liabilities	16	36	61	98	86	68	78	153	156	86	47
Accounts Payable	4.70	6.60	4.21	5.13	4.16	3.00	2.82	2.81	1.46	1.09	1.30
Accrued Expenses	4.91	8.82	16	27	30	23	34	24	18	12	14
Current Deferred Revenue	6.13	20	41	53	51	42	41	121	132	67	27
Other Current Liabilities	-	-	-	-	-	-	-	4.08	4.59	5.15	4.24
Total Noncurrent Liabilities	55	85	267	228	205	298	262	194	93	35	5.94
Capital Lease Obligations	-	-	-	-	25	22	18	14	9.39	4.24	0.00
Noncurrent Deferred Revenue	55	84	265	225	179	277	244	180	80	27	1.59
Other Noncurrent Operating Liabilities	0.20	0.57	1.90	3.05	0.85	-	-	0.00	3.89	4.12	4.35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	126	78	70	131	51	-7.77	-0.46	-86	-47	-0.46	99
Total Preferred & Common Equity	126	78	70	131	51	-7.77	-0.46	-86	-47	-0.46	99
Preferred Stock	-	0.00	-	-	0.00	-	-	0.00	0.00	0.00	0.00
Total Common Equity	126	78	70	131	51	-7.77	-0.46	-86	-47	-0.46	99
Common Stock	244	255	289	446	468	500	623	637	676	691	811
Retained Earnings	-117	-176	-219	-315	-417	-508	-624	-723	-723	-692	-712
Accumulated Other Comprehensive Income / (Loss)	-0.08	-0.03	-0.09	-0.09	0.06	-0.05	-0.24	0.01	0.10	0.03	0.11

This table presents CytomX Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	209	221	185	159	139	98	175	158
Total Current Assets	188	201	167	143	124	87	165	149
Cash & Equivalents	58	26	36	43	41	48	49	34
Short-Term Investments	123	168	114	94	77	32	109	109
Accounts Receivable	1.90	2.42	13	2.78	3.35	1.96	1.87	1.63
Prepaid Expenses	5.04	4.68	3.79	3.12	3.24	4.79	4.67	3.96
Plant, Property, & Equipment, net	4.50	4.06	3.57	3.32	2.94	2.23	1.95	1.72
Total Noncurrent Assets	17	16	14	13	12	9.64	8.49	7.32
Goodwill	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
Intangible Assets	0.80	0.77	0.69	0.66	0.62	0.55	0.51	0.47
Other Noncurrent Operating Assets	15	14	12	11	10	8.14	7.03	5.89
Total Liabilities & Shareholders' Equity	209	221	185	159	139	98	175	158
Total Liabilities	294	272	216	190	162	73	55	51
Total Current Liabilities	141	147	145	143	119	50	39	41
Accounts Payable	1.03	1.71	1.96	0.61	1.42	0.28	0.23	0.65
Accrued Expenses	20	21	14	14	17	11	12	12
Current Deferred Revenue	120	124	124	124	96	33	22	22
Other Current Liabilities	-	-	4.72	4.86	5.00	5.29	5.44	5.60
Total Noncurrent Liabilities	153	126	72	48	43	23	16	9.84
Capital Lease Obligations	12	11	8.15	6.89	5.60	2.86	1.44	0.00
Noncurrent Deferred Revenue	141	112	60	37	34	16	10	5.54
Other Noncurrent Operating Liabilities	0.22	2.76	3.94	3.99	4.05	4.18	4.24	4.30
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-85	-51	-32	-31	-23	25	120	107
Total Preferred & Common Equity	-85	-51	-32	-31	-23	25	120	107
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-85	-51	-32	-31	-23	25	120	107
Common Stock	642	673	678	685	687	693	788	790
Retained Earnings	-727	-724	-710	-716	-710	-668	-668	-682
Accumulated Other Comprehensive Income / (Loss)	0.04	-0.06	-0.01	-0.00	0.04	-0.00	0.03	0.10

This table displays calculated financial ratios and metrics derived from CytomX Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	36,024,292.00	36,402,346.00	38,408,626.00	45,007,104.00	45,434,164.00	46,224,402.00	65,249,116.00	66,084,367.00	66,988,904.00	78,258,879.00	170,186,742.00
DEI Adjusted Shares Outstanding	36,024,292.00	36,402,346.00	38,408,626.00	45,007,104.00	45,434,164.00	46,224,402.00	65,249,116.00	66,084,367.00	66,988,904.00	78,258,879.00	170,186,742.00
DEI Earnings Per Adjusted Shares Outstanding	-1.17	-1.62	-1.12	-1.88	-2.92	-1.40	-1.78	-1.50	-0.01	0.41	-0.12
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-23	-42	-32	-55	-99	-56	-81	-71	1.11	25	-16
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-2.92%	655.93%	-15.81%
Earnings before Interest and Taxes (EBIT)	-35	-60	-46	-78	-142	-81	-116	-101	-6.51	25	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-35	-56	-44	-78	-141	-78	-113	-99	-12	21	-23
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-25	0.19	168	-53	-184	26	-96	-93	-52	-91	-74
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-62	-103	-304	-305	-220	-302	-288	-265	-213	-97	-38
Increase / (Decrease) in Invested Capital	1.78	-42	-201	-1.03	85	-82	15	22	53	116	59
Book Value per Share	$3.50	$2.16	$1.82	$2.91	$1.13	($0.17)	($0.01)	($1.30)	($0.71)	($0.01)	$0.58
Tangible Book Value per Share	$3.42	$2.08	$1.75	$2.85	$1.08	($0.21)	($0.04)	($1.33)	($0.73)	($0.03)	$0.58
Total Capital	126	78	70	131	76	14	18	-72	-38	3.78	99
Total Debt	0.00	0.00	0.00	0.00	25	22	18	14	9.39	4.24	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	25	22	18	14	9.39	4.24	0.00
Net Debt	-187	-182	-374	-436	-271	-294	-287	-180	-165	-96	-137
Capital Expenditures (CapEx)	1.59	2.12	1.56	3.79	3.50	2.31	1.61	1.74	0.84	0.31	0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-13	-30	-47	-89	-78	-60	-73	-109	-147	-79	-40
Debt-free Net Working Capital (DFNWC)	174	152	327	348	218	256	232	84	27	22	97
Net Working Capital (NWC)	174	152	327	348	218	256	232	84	27	22	97
Net Nonoperating Expense (NNE)	12	17	11	30	34	8.44	35	28	1.68	-7.05	1.71
Net Nonoperating Obligations (NNO)	-188	-182	-374	-436	-271	-294	-287	-180	-165	-96	-137
Total Depreciation and Amortization (D&A)	-0.10	3.40	2.03	0.18	0.38	2.34	2.98	2.39	-5.24	-3.54	-0.83
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($1.16)	($2.03)	($2.26)	$0.00	($1.30)	$0.00	($0.01)	$0.38	($0.15)
Adjusted Weighted Average Basic Shares Outstanding	36.08M	36.52M	38.61M	45.11M	45.57M	64.78M	65.39M	0.00	73.81M	84.44M	137.94M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($1.16)	($2.03)	($2.26)	$0.00	($1.30)	$0.00	($0.01)	$0.38	($0.15)
Adjusted Weighted Average Diluted Shares Outstanding	36.08M	36.52M	38.61M	45.11M	45.57M	64.78M	65.39M	0.00	73.81M	84.75M	137.94M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($1.16)	($2.03)	($2.26)	$0.00	($1.30)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	8.60M	36.23M	37.17M	41.66M	45.34M	46.15M	64.15M	0.00	67.72M	80.10M	170.19M
Normalized Net Operating Profit after Tax (NOPAT)	-23	-42	-32	-55	-99	-56	-81	-71	-4.54	25	-16
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from CytomX Therapeutics' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
DEI Shares Outstanding	66,338,938.00	66,767,779.00	66,988,904.00	67,721,658.00	67,721,658.00	78,117,601.00	78,258,879.00	80,099,889.00	80,621,293.00	164,912,906.00	170,186,742.00
DEI Adjusted Shares Outstanding	66,338,938.00	66,767,779.00	66,988,904.00	67,721,658.00	67,721,658.00	78,117,601.00	78,258,879.00	80,099,889.00	80,621,293.00	164,912,906.00	170,186,742.00
DEI Earnings Per Adjusted Shares Outstanding	-0.02	0.04	0.01	0.20	-0.10	0.07	0.24	0.29	0.00	-0.09	-0.17
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-2.34	1.61	-0.27	12	-5.92	4.07	18	23	-0.90	-11	-20
Return On Investment Capital (ROIC_SIMPLE)	-	-	0.70%	-49.36%	24.31%	-22.78%	465.65%	80.85%	-0.74%	-10.28%	-19.75%
Earnings before Interest and Taxes (EBIT)	-3.40	3.12	-0.60	12	-8.45	4.10	18	23	-1.27	-16	-28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.51	1.67	-2.34	10	-9.43	3.31	17	23	-1.32	-16	-28
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	88	86	-53	-93	-99	-95	-98	-99	-126	-110	-78
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-254	-235	-213	-174	-162	-135	-97	-52	-37	-36	-38
Increase / (Decrease) in Invested Capital	-91	-84	53	104	93	99	116	122	125	99	59
Book Value per Share	($1.28)	($0.77)	($0.71)	($0.47)	($0.37)	($0.30)	($0.01)	$0.31	$1.49	$0.65	$0.58
Tangible Book Value per Share	($1.31)	($0.79)	($0.73)	($0.49)	($0.39)	($0.32)	($0.03)	$0.29	$1.47	$0.64	$0.58
Total Capital	-73	-41	-38	-24	-24	-18	3.78	28	121	107	99
Total Debt	12	11	9.39	8.15	6.89	5.60	4.24	2.86	1.44	0.00	0.00
Total Long-Term Debt	12	11	9.39	8.15	6.89	5.60	4.24	2.86	1.44	0.00	0.00
Net Debt	-169	-184	-165	-142	-130	-112	-96	-77	-157	-144	-137
Capital Expenditures (CapEx)	0.52	0.01	0.27	0.12	0.10	0.02	0.08	0.12	0.03	-0.13	0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-134	-140	-147	-128	-137	-113	-79	-43	-33	-35	-40
Debt-free Net Working Capital (DFNWC)	46	54	27	23	0.22	4.95	22	36	125	108	97
Net Working Capital (NWC)	46	54	27	23	0.22	4.95	22	36	125	108	97
Net Nonoperating Expense (NNE)	-1.26	-1.39	-1.10	-2.18	0.62	-1.67	-1.26	-0.96	-0.75	3.19	6.96
Net Nonoperating Obligations (NNO)	-169	-184	-165	-142	-130	-112	-96	-77	-157	-144	-137
Total Depreciation and Amortization (D&A)	-1.12	-1.45	-1.74	-1.40	-0.98	-0.79	-0.37	-0.07	-0.05	-0.50	-0.21
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.02)	$0.04	$0.02	$0.17	($0.08)	$0.07	$0.22	$0.27	$0.00	($0.09)	($0.33)
Adjusted Weighted Average Basic Shares Outstanding	66.54M	80.73M	73.81M	82.03M	84.88M	85.09M	84.44M	87.12M	129.08M	165.00M	137.94M
Adjusted Diluted Earnings per Share	($0.02)	$0.04	$0.02	$0.17	($0.08)	$0.07	$0.22	$0.27	$0.00	($0.09)	($0.33)
Adjusted Weighted Average Diluted Shares Outstanding	66.54M	80.99M	73.81M	82.63M	84.88M	85.20M	84.75M	87.15M	129.08M	165.00M	137.94M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	66.77M	66.99M	67.72M	0.00	78.12M	78.26M	80.10M	80.62M	164.91M	169.44M	170.19M
Normalized Net Operating Profit after Tax (NOPAT)	-2.34	1.61	-0.42	12	-5.92	4.07	18	23	-0.90	-11	-20
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

Financials Breakdown Chart

Key Financial Trends

Here’s a concise, investor-focused read on CytomX Therapeutics (CTMX) using the latest quarterly data (last four years, through Q4 2025). The company shows ongoing cash burn and losses, but has intermittently boosted liquidity through equity financing and occasional investment sales. Revenue in 2025 has been highly volatile, with a sharp pullback after a mid-year spike. Key trends below summarize what matters most for near-term liquidity and funding needs.

CTMX raised about $16.64 million via common equity in Q2 2025 and again around $16.64 million in Q4 2025, supporting liquidity for ongoing operations.
Net cash from financing activities was positive in Q1 2025 (~$9.55 million) and again in Q2 2025 (~$16.64 million), helping to fund operations during a period of cash burn.
Investing activities delivered cash inflows from investment sales in several periods, including $64.999 million from sales in Q4 2024, and $32.5 million (Q2 2025), $20.0 million (Q3 2025), and $30.0 million (Q4 2025) from investment maturities/sales in 2025.
Revenue is highly volatile in 2025, with Q1 revenue about $50.9 million, then dropping to roughly $18.7 million (Q2), $5.96 million (Q3), and $0.663 million (Q4), which reduces visibility for sustainable top-line growth.
The balance sheet shows a substantial accumulated deficit embedded in Retained Earnings, offset by equity instruments (e.g., common stock). This highlights ongoing funding needs to support operations.
R&D remains a major cost driver (Q4 2025 RD expense about $21.2 million; Q3 2025 ≈ $15.3 million; Q2 2025 ≈ $13.3 million; Q1 2025 ≈ $18.9 million), typical for a biotech in development phase.
Operating cash flow from continuing activities is negative in every 2025 quarter (Q4 −$23.2M; Q3 −$15.5M; Q2 −$15.8M; Q1 −$21.0M), indicating ongoing cash burn.
Net income in 2025 quarters shows meaningful losses (e.g., Q4 −$26.5M; Q3 −$14.2M; Q2 −$0.15M; Q1 +$23.5M), underscoring profitability challenges and volatility in quarterly results.
Dependence on equity financing and uneven financing inflows imply dilution risk and a need for continued external funding to cover sustained losses.
Together with persistent operating losses and negative cash flow, the business model currently relies on external funding to fund R&D and operations, a common dynamic for early-stage biotech but a consideration for investors assessing long-term profitability and capital efficiency.

05/14/26 05:24 PM ETAI Generated. May Contain Errors.

CytomX Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CytomX Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

CytomX Therapeutics' net income appears to be on a downward trend, with a most recent value of -$17.37 million in 2025, falling from -$35.37 million in 2015. The previous period was $31.87 million in 2024. See CytomX Therapeutics' forecast for analyst expectations on what's next for the company.

CytomX Therapeutics' total operating income in 2025 was -$22.36 million, based on the following breakdown:

Total Gross Profit: $76.20 million
Total Operating Expenses: $98.57 million

Over the last 10 years, CytomX Therapeutics' total revenue changed from $7.71 million in 2015 to $76.20 million in 2025, a change of 888.1%.

CytomX Therapeutics' total liabilities were at $52.56 million at the end of 2025, a 56.6% decrease from 2024, and a 26.1% decrease since 2015.

In the past 10 years, CytomX Therapeutics' cash and equivalents has ranged from $12.67 million in 2025 to $247.58 million in 2018, and is currently $12.67 million as of their latest financial filing in 2025.

Over the last 10 years, CytomX Therapeutics' book value per share changed from 3.50 in 2015 to 0.58 in 2025, a change of -83.3%.

Related Companies

Financial statements for NASDAQ:CTMX last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytomX Therapeutics (CTMX) Financials

Financials Breakdown Chart

Key Financial Trends

CytomX Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytomX Therapeutics (CTMX) Financials

Annual Income Statements for CytomX Therapeutics

Quarterly Income Statements for CytomX Therapeutics

Annual Cash Flow Statements for CytomX Therapeutics

Quarterly Cash Flow Statements for CytomX Therapeutics

Annual Balance Sheets for CytomX Therapeutics

Quarterly Balance Sheets for CytomX Therapeutics

Annual Metrics And Ratios for CytomX Therapeutics

Quarterly Metrics And Ratios for CytomX Therapeutics

Financials Breakdown Chart

Key Financial Trends

CytomX Therapeutics Financials - Frequently Asked Questions

When does CytomX Therapeutics' fiscal year end?

How has CytomX Therapeutics' net income changed over the last 10 years?

What is CytomX Therapeutics' operating income?

How has CytomX Therapeutics' revenue changed over the last 10 years?

How much debt does CytomX Therapeutics have?

How much cash does CytomX Therapeutics have?

How has CytomX Therapeutics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools